Navigation Links
EnVivo Initiates Phase IIb Alzheimer's Disease Trial For EVP-6124
Date:5/11/2010

.

Two previous studies with EVP-6124 in Alzheimer's disease patients demonstrated that it was well tolerated and produced significant effects on a variety of cognitive measures of brain function such as attention, memory and executive function (complex thinking tasks). EVP-6124 had procognitive effects in two separate clinical trials: one study conducted in Alzheimer's disease patients already treated with Acetyl Choline Esterase Inhibitors (AChEI) and one in Alzheimer's disease patients not on AChEI therapy (naive patients).

EVP-6124 is a selective agonist for the alpha-7 subtype of the nicotinic acetylcholine receptor and is being developed by EnVivo for potential cognitive enhancement in both schizophrenia and Alzheimer's patients. It has been shown to have excellent CNS penetration, oral bioavailability, pharmacokinetics and metabolic profile.

About EnVivo Pharmaceuticals

EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system, with a current focus on Alzheimer's disease, cognitive disorders and schizophrenia. The company's lead product is an alpha-7 nicotinic acetylcholine receptor agonist and has been tested in Phase IIa clinical trials for cognition disorders in Alzheimer's disease and schizophrenia. The company's other programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi) with EVP-0334 as the lead molecule for cognition in Alzheimer's disease which has completed Phase I studies, and seve
'/>"/>

SOURCE EnVivo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
2. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
3. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
4. EnVivo Pharmaceuticals Announces Executive Appointment
5. Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd.
6. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
7. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
8. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
9. Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union
10. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
11. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 Pharma Packaging ... position themselves for their 89th year in ... encoding, Pharma Packaging Solutions is preparing packaging ... software and new procedures. Establishing training and ... Practices (cGMP), Pharma Packaging Solutions will be ...
(Date:9/16/2014)... 16, 2014  LABSCO, the leading specialty sales ... hospitals, physician office laboratories and alternate healthcare settings ... 2014, it will serve as Siemens Healthcare Diagnostics, ... and as a semi-exclusive sales distributor in specified ... United States . LABSCO will be ...
(Date:9/16/2014)...  Ascendis Pharma A/S, a biotechnology company that ... unmet medical needs, today announced positive interim results ... evaluate once-weekly TransCon Growth Hormone in children with ... results will be presented at the 7th International ... held October 15-18, 2014, in Singapore.  ...
(Date:9/16/2014)... 16, 2014 BCC Research reveals ... STEM CELLS , the global market for stem cells ... 2018, with a five-year compound annual growth rate (CAGR) ... the Americas with growth projections of $2.2 billion in ... (Logo: http://photos.prnewswire.com/prnh/20140805/700528) , Unlike other potential applications ...
Breaking Biology Technology:Adding Serialization Capabilities and Expanded Capacity, Pharma Packaging Solutions Is Preparing for 89th Year of Business 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 2Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 3
... OF INDUSTRY, Calif. and HONG KONG, June 30 EFT BioTech ... has successfully completed its inaugural Taiwan Strait passenger voyage which has ... the Taiwan Sun, and the Qatar Tribune. The article states: ... with China on Sunday, making it the first such cross-strait service ...
... Mass., June 30 Microfluidics, a wholly owned ... MFLU), and Particle Sciences Inc. (PSI) have formed ... the most advanced and reliable nanotechnology and formulation ... Pharmaceutical Ingredients (APIs). , , Particle Sciences ...
... from the Taichung Harbor to Xiamen , China ... , , CITY OF INDUSTRY, Calif. and HONG ... announced today that the Company,s subsidiary, Excalibur International Marine Corporation, completed ... 2009. The voyage across the Taiwan Strait takes only 4 ...
Cached Biology Technology:Excalibur International Marine (49% Owned by EFT BioTech Holdings) Completes Inaugural Passenger Crossing of Taiwan Strait 2Excalibur International Marine (49% Owned by EFT BioTech Holdings) Completes Inaugural Passenger Crossing of Taiwan Strait 3Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization 2Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization 3EFT BioTech Holdings, Inc.'s Sea Vessel Completes Inaugural Passenger Voyage Across the Taiwan Strait 2EFT BioTech Holdings, Inc.'s Sea Vessel Completes Inaugural Passenger Voyage Across the Taiwan Strait 3
(Date:9/16/2014)... Johns Hopkins neuroscientists have discovered the "molecular brakes" that ... ear cochleas of mice. These "hair cells" translate sound ... brain and are interpreted as sounds. If the arrangement ... , A summary of the research will be published ... 16. , "The proteins Hey1 and Hey2 act as ...
(Date:9/16/2014)... the dinosaurs 66 million years ago decimated the evergreens ... than their deciduous peers, according to a study led ... journal PLOS Biology . , Applying biomechanical ... leaves of angiosperms flowering plants excluding conifers ... of a diverse plant community thriving during a 2.2 ...
(Date:9/16/2014)... Hesperides vessel returned to Spain culminating the around the ... clear picture of how the global ocean works and ... pollutants from the atmosphere is not limited to coastal ... of the planet, and it is already affecting the ... week in CSIC Residence for Researchers in Barcelona, in ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 2The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 3
... is on the rise and may be problematic, according ... the December issue of Obstetrics & Gynecology, Erin Tracy, ... and may present potential pitfalls for patients and physicians. ... have no proven clinical validity whatsoever and are quite ...
... for advanced age-related macular degeneration, researchers from Harvard and ... the cure. A research report published in the December ... endostatin to mice significantly reduced or eliminated abnormal blood ... the disease causes blindness. Our study provides ...
... brain injury and using club drugs have in common" ... chemical chain reaction in the brain, leading to cell death, ... series of studies at UF over the past five years ... MDMA, and other forms of methamphetamine lead to the same ...
Cached Biology News:Direct-to-consumer advertising for genetic tests concerns physicians and may mislead patients 2New treatment for age-related macular degeneration within sight 2Club drugs inflict damage similar to traumatic brain injury 2Club drugs inflict damage similar to traumatic brain injury 3
Request Info...
Automated -80° C sample library for microplates and cryotube racks in SBS format; for integration into automated processes....
... Oxidized LDL (Competitive) EIA Principle: ... the monoclonal antibody 4E6. Oxidized LDL in the ... LDL bound to the microtiter well for the ... a washing st Sample Size: 25 ...
... BUF040A is a diluent that is designed for ... which are paired with a mouse monoclonal coating ... rabbit and mouse proteins to prevent non-specific binding ... • This buffer may be used ...
Biology Products: